Mucositis paclitaxel

Paclitaxel Infection, nausea, vomiting, diarrhea, mucositis, arthralgia, Mild (day 1 only)... 

Paclitaxel -natural taxane inhibits depolymerization of tubulin in mitotic spindle apparatus -bone marrow suppression -nausea and vomiting—mild -mucocutaneous effects (mucositis, stomatitis, diarrhea) -hypersensitivity reactions -peripheral neuropathy -myalgias, arthralgias -mild vesicant... 

The common link with many clinical studies of chemoradiation in head and neck cancers is the significant mucositis that patients experience during therapy. Acrein has reported on a trial that attempts to deliver Ethyol as a protective agent to lessen the side effects of weekly paclitaxel (134). 

Hoffman and colleagues evaluated the effects of a 1 h weekly infusion of paclitaxel (20 mg/m2, escalating by 10 mg/m2 increments) with conventional radiotherapy (35). The MTD was 30 mg/m2/wk with the dose-limiting toxicity being mucositis. 

The efficacy and toxicity of Caelyx in combination with paclitaxel (Taxol) were investigated as a first-line therapy in 34 patients with advanced breast cancer in a multicentric phase II study [428], Paclitaxel at a dose of 175 mg/m2 and Caelyx (30 mg/m2) were administered intravenously every 3 weeks. It was shown that the response rates of the combination were over 70% while the median time to treatment failure was 45 weeks. No significant clinical cardiotoxicity was observed and the usual side effects (mucositis, stomatitis, hand-foot syndrome) were treated accordingly. 

CYCLOPHOSPHAMIDE PACLITAXEL t risk of neutropenia, thrombocytopenia and mucositis when paditaxel is infused over 24 or 72 hours prior to cyclophosphamide Mechanism is uncertain Administer cyclophosphamide first and then follow with paditaxel... 

Mucositis and stomatitis have been reported with paclitaxel. Mucositis is characterized by ulceration of the lips, pharynx, and oral cavity, occurring 3-7 days after paclitaxel treatment (1,13,14,17,24,26,29,33,36-38). Mucositis appears to be more common during treatment of acute leukemias rather than solid tumors, when doses above 390 mg/m are used (24). Severe mucositis occurred during second and third courses, suggesting a cumulative effect, and was more severe if treatment was given at 15 days or less after previous courses. Patients... 

Postmortem examinations of patients treated with paclitaxel have shown mucosal ulceration of the esophagus, stomach, small intestine, and colon (40). Changes associated with epithelial necrosis and mitotic arrest were most prominent in patients who had recently been treated with paclitaxel. These findings suggest that paclitaxel causes transient mitotic arrest associated with cell... 

Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 2009 19(4) 238 2. 

---